Long-term treatment with human immunoglobulin for antisynthetase syndrome-associated interstitial lung disease.

Affiliation

Division of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, United States. Electronic address: [Email]

Abstract

Interstitial lung disease-associated antisynthetase syndrome (AS-ILD) carries significant morbidity and mortality. Corticosteroids and immunosuppressive drugs are the mainstay of treatment. Human immunoglobulin (IVIg), an immunomodulator without immunosuppressive properties, is effective in myositis but the evidence supporting its use in ILD is scarce.

Keywords

Antisynthetase syndrome and refractory disease,Human intravenous immunoglobulin,Interstitial lung disease,Therapy,

OUR Recent Articles